Evaluation of platelets transfusion in patients undergoing high dose chemotherapy for bone marrow transplantation
DOI:
https://doi.org/10.46765/2675-374X.2020v1n1p19-26Keywords:
BMT, Endothelial lesion, Platelet refractoriness, Platelets transfusionAbstract
Introduction: Microvascular endothelial damage is a well-recognized complication of bone marrow transplantation (BMT) and the mechanisms of this disorder are still poorly understood. The objective of this scenario is to evaluate the relationship between inflammatory markers and other factors that influence platelet consumption and platelet transfusion yield, as well as the presence of embolic and / or vascular thrombotic events in patients submitted to high-dose chemotherapy conditioning for Bone marrow transplant.
Material and Methods: Prospective analysis of patients, including 25 patients who underwent autologous and allogenic BMT. The patients were evaluated in relation to previous radiotherapy, CD34 + cell count, period of neutropenia, body mass index (BMI), ferritin, reactive C protein (RCP), relating these factors to the number of platelet transfusions, platelet refractoriness and vascular events such as sinusoidal obstruction syndrome (SOS) and bone marrow grafting syndrome.
Results: Only BMI> 25 Kg / m2 of the studied variables presented a statistically significant value (p = 0.003) in relation to the lower need for transfusion of platelet concentrate. For platelet refractoriness and / or vascular events none of the variables was statistically significant. The conditions found in the 3 cases of platelet refractoriness and in the 2 cases of vascular events have characteristics like those described in the literature.
Conclusion: Although the cause is unclear, we agree with data reported in the literature that patients with high BMI have a lower need for transfusion of platelets. Small sampling limits our comparisons and significant statistical inference; however, we cannot rule out the relevance of a descriptive analysis of the results, especially if we consider that each patient should be evaluated in an individualized way in clinical practice.
Downloads
Published
How to Cite
Issue
Section
License
License and Copyright Policy
The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.
-
License
- All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
- This license permits anyone to:
- Share: Copy and redistribute the material in any medium or format.
- Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
- The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.
More information about the license can be found here: Creative Commons Attribution 4.0 International License.
-
Authors’ Rights
- Authors retain the copyright to their work.
- Authors grant JBMTCT the right to publish the work and make it openly accessible online.
- Authors are free to:
- Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
- Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.
-
No Embargo
- There is no embargo period; articles are made freely available immediately upon publication.
-
Ethical Use
- Users of JBMTCT articles must ensure proper citation of the authors and the journal.
- Articles must not be used in ways that violate ethical or legal standards.
-
Disclaimer
- While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.
For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br
JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.